食管癌和胃癌患者的最佳协作管理
Optimal Collaborative Management of Patients With Esophagogastric Cancers.
作者信息
Ilson David, Malangone Steve
机构信息
Memorial Sloan Kettering Cancer Center, New York, New York.
University of Arizona Cancer Center, Tucson, Arizona.
出版信息
J Adv Pract Oncol. 2017 Apr;8(3):237-242. doi: 10.6004/jadpro.2017.8.3.4. Epub 2017 Apr 1.
Abstract
The addition of radiation to preoperative chemotherapy and newer therapeutic combinations add to treatment options for these difficult-to-treat cancers.
摘要
在术前化疗中加入放疗以及采用更新的治疗组合，为这些难以治疗的癌症增加了治疗选择。
相似文献
1
Optimal Collaborative Management of Patients With Esophagogastric Cancers.食管癌和胃癌患者的最佳协作管理
J Adv Pract Oncol. 2017 Apr;8(3):237-242. doi: 10.6004/jadpro.2017.8.3.4. Epub 2017 Apr 1.
2
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.比较局部进展期胃癌或食管胃结合部腺癌患者术前放化疗与术前化疗的随机 III 期临床试验方案：PREACT。
BMC Cancer. 2019 Jun 20;19(1):606. doi: 10.1186/s12885-019-5728-8.
3
Advances in the treatment of gastric cancer.胃癌治疗的进展
Curr Opin Gastroenterol. 2017 Nov;33(6):473-476. doi: 10.1097/MOG.0000000000000395.
4
[CLINICAL RECOMMENDATIONS FOR DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH ESOPHAGEAL AND ESOPHAGOGASTRIC JUNCTION CANCERS].[食管癌和食管胃交界癌患者的诊断、治疗及监测临床建议]
Lijec Vjesn. 2016 Sep-Oct;138(9-10):233-9.
5
An update in the nonendoscopic treatment of gastric cancer.
Curr Opin Gastroenterol. 2016 Nov;32(6):501-506. doi: 10.1097/MOG.0000000000000314.
6
Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?食管癌和胃癌有精确的辅助治疗方法吗？
Am Soc Clin Oncol Educ Book. 2018 May 23;38:280-291. doi: 10.1200/EDBK_200785.
7
[A Case of cStage Ⅲ Esophagogastric Junction Adenocarcinoma That Showed pCR to Preoperative Chemotherapy Containing SOX].[1例Ⅲ期食管胃交界腺癌对含SOX的术前化疗显示病理完全缓解]
Gan To Kagaku Ryoho. 2018 Dec;45(13):2369-2371.
8
Multidisciplinary approach to esophageal and gastric cancer.食管癌和胃癌的多学科治疗方法。
Surg Clin North Am. 2000 Apr;80(2):659-82; discussions 683-6. doi: 10.1016/s0039-6109(05)70205-x.
9
Esophageal and esophagogastric junction cancers, version 1.2015.食管和胃食管交界处癌，第 1.2015 版。
J Natl Compr Canc Netw. 2015 Feb;13(2):194-227. doi: 10.6004/jnccn.2015.0028.
10
[A case of HER2-positive esophagogastric junction cancer treated by using a neoadjuvant chemotherapy regimen consisting of trastuzumab].1例采用曲妥珠单抗新辅助化疗方案治疗的HER2阳性食管胃交界癌
Gan To Kagaku Ryoho. 2014 Nov;41(12):2285-6.
本文引用的文献
1
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.帕博利珠单抗治疗 PD-L1 阳性晚期胃癌患者（KEYNOTE-012）：一项多中心、开放标签、Ib 期临床试验。
Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.
2
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.随机多中心 II 期研究：改良多西紫杉醇、顺铂和氟尿嘧啶（DCF）对比 DCF 联合生长因子支持治疗转移性胃腺癌患者：美国胃癌联盟研究。
J Clin Oncol. 2015 Nov 20;33(33):3874-9. doi: 10.1200/JCO.2015.60.7465.
3
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.新辅助放化疗联合手术与单纯手术治疗食管或食管胃交界癌（CROSS）：一项随机对照临床试验的长期结果。
Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
4
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.雷莫芦单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗的晚期胃或胃食管结合部腺癌患者（RAINBOW）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
5
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.含奥沙利铂 FOLFOX 方案与氟尿嘧啶和顺铂方案在食管癌患者中的确证放化疗比较（PRODIGE5/ACCORD17）：一项随机、2/3 期试验的最终结果。
Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18.
6
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.食管腺癌的外显子组和全基因组测序鉴定出反复出现的驱动事件和突变复杂性。
Nat Genet. 2013 May;45(5):478-86. doi: 10.1038/ng.2591. Epub 2013 Mar 24.
7
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
8
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.S0356：一项 II 期临床和前瞻性分子试验，奥沙利铂、氟尿嘧啶和外照射放疗联合术前治疗食管腺癌患者。
J Clin Oncol. 2011 Dec 1;29(34):4555-60. doi: 10.1200/JCO.2011.36.7490. Epub 2011 Oct 24.
9
Validation of the updated 7th edition AJCC TNM staging criteria for gastric adenocarcinoma.验证更新的第 7 版 AJCC TNM 分期标准在胃腺癌中的应用。
J Gastrointest Surg. 2012 Jan;16(1):53-61; discussion 61. doi: 10.1007/s11605-011-1707-3. Epub 2011 Oct 5.
10
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.曲妥珠单抗联合化疗与单纯化疗治疗 HER2 阳性晚期胃或胃食管交界腺癌（ToGA）：一项开放标签、随机对照的 3 期临床试验。
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
Zotero 插件